ERBB2 and breast carcinoma: The Breast cancer trials of OraL EveROlimus-3 (BOLERO-3) trial showed that triple therapy with vinorelbine, trastuzumab, and everolimus was superior to vinorelbine, trastuzumab, and placebo in trastuzumab-resistant advanced HER2+ breast cancer [53].